# Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

> **NCT02052193** · PHASE2 · TERMINATED · sponsor: **University Hospital Tuebingen** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Melanoma (Carrying BRAF V600 Mutation)

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT02052193
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12-15
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Second cohort not opened because Simon-Two\_Step model failed
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052193, "Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02052193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*